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ABSTRACT 
Alginate nanofibers were prepared in the presence of poly(ethylene oxide) (PEO), a surfactant 
Pluronic F-127, and a model drug (ciprofloxacin hydrochloride, CpHCl), all mixed prior to 
electrospinning. It was demonstrated that addition of a carrier polymer (PEO) and a small 
amount of surfactant are necessary to obtain uniform alginate fibers with cylindrical shape 
and regular morphology. Importantly, PEO was completely removed from the resulting 
nanofibers during crosslinking and stabilization post-treatment. The stable alginate fibers 
loaded with CpHCl were examined by scanning electron microscopy and the average 
diameter of the fibers ranged from 109 nm (unloaded fibers) to 161 nm (loaded fibers). The 
release of a studied antibiotic from the nanofibers, characterized by a final loading efficiency 
of 51%, was tested in physiological conditions. It was revealed that ca. 24% of CpHCl is 
released during first 20h with combined transport mechanism, however with the predominant 
contribution of Fickian diffusion. 
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1. Introduction 
Electrospinning is a simple and versatile method for fabrication of continuous and 
uniform polymeric nanofibers. Various synthetic polymers (e.g. PCL, PLA, PGLA, etc.) have 
been successfully electrospun into ultrafine fibers [1-3]. While natural polymers (e.g. 
chitosan, sodium alginate, hyaluronic acid, etc.) usually need to be electrospun in blend form 
by mixing them with synthetic polymers such as PEO, PVA or PVP, which improves their 
electrospinning processability [4-8]. High specific area, tunable pore size, controlled 
mechanical properties, and their ability to interact with cells in a manner which mimics the 
natural ECMs mainly cause that fibrous materials are finding an increasing range of 
applications, including biomedical areas e.g. antibacterial fibers for wound dressings [9], 
scaffolds for tissue engineering (i.e. skin, bone, cartilage and cardiac tissue) [5, 10, 11], drug 
delivery systems [12, 13], medical implants, protective textiles, filtration systems, etc. [7, 8, 
14-17]. 
Alginate was found to possess many significant and desirable properties as material 
for wound dressing such as decent water absorptivity, conformability, optimal water vapor 
transmission rate, and mild antiseptic properties coupled with non-toxicity, non-
immunogenicity, and biocompability [4, 8, 18]. In particular, when alginate is combined with 
well-known biocides (e.g. antibiotics, metal nanoparticles, etc.) it forms an effective 
antibacterial wound dressing, that offers many advantages including hemostatic capability, 
gel-forming ability upon absorption of wound exudates and last but not least well-defined 
drug delivery system. For instance, it has been suggested that alginate dressings (e.g. 
Kaltostat®) can enhance wound healing by stimulating monocytes to produce elevated levels 
of cytokines such as interleukin-6 and tumor necrosis factor-α. Production of these cytokines 
at wound sites results in pro-inflammatory factors that are advantageous to wound healing 
[19]. 
Electrospinning of alginate is still a challenging task, since sodium alginate is a 
polyelectrolyte having high conductivity and surface tension. Even though alginate can form 
solutions with a wide range of viscosity, in this case viscosity is not a limiting factor but the 
repulsive force among the polyanions are the key factor hindering electrospinning of sodium 
alginate [20]. These repulsive forces can be reduced by interactions between PEO and sodium 
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alginate occurring after blending. Thus, it allows successful electrospinning of sodium 
alginate/PEO blends [6, 7, 21, 22]. 
In this paper, we present a simple method of electrospinning of sodium alginate 
nanofibers loaded with ciprofloxacin hydrochloride, a fluoroquinolone antibiotic that is 
widely used for wound healing applications. Alginate blended with poly(ethylene oxide) was 
electrospun into fibers loaded with the above-mentioned antibiotic from an aqueous solution. 
Thus, the cytotoxicity, usually involved in preparing the electrospun mats by using toxic 
solvents, was minimized in this method due to application of only biocompatible materials. 
Effect of an additional polymer, a surfactant, and alginate concentration on formation of fibers 
was studied in detail. Moreover, kinetics of antibiotic release from well-characterized stable 
alginate hybrid fibers was studied in a physiological fluid (phosphate-buffered saline, 
pH = 7.4). 
 
2. Experimental section 
2.1. Materials 
Sodium alginate (AL), extracted from seaweed Macrocystis pyrifera, was purchased 
from Sigma-Aldrich. According to manufacturer, a viscosity of a 1% AL solution at 25°C is 
5.0  40.0 cP. Poly(ethylene oxide) (PEO, MW 100, 600, 1000 and 2000 kDa), Triton X-100, 
Pluronic F-127, ciprofloxacin hydrochloride (CpHCl), ethanol and calcium chloride were also 
purchased from Sigma-Aldrich. All reagents were used without any further purification. 
 
2.2. Fabrication of alginate-based electrospun fibers loaded with ciprofloxacin hydrochloride 
Sodium alginate, PEO and ciprofloxacin hydrochloride were dissolved in water at the 
desired final concentrations in ranges from: 1-5 wt.%, 1.5-3 wt.% and 0.02-0.48 wt.% (0.2-
4.8 mg/ml), respectively. Then, the surfactants: Triton X-100 or Pluronic F-127 were added at 
final concentrations of 0.5-1 wt.%. The prepared mixtures were stirred overnight at room 
temperature. 
An Yflow 2.2 D500 electrospinner with a coaxial setup was used to obtain the fibers 
that were collected on a plate covered with Parchment paper for easy removal of mats. The 
polymer solution was pumped through a syringe with a 22 gauge needle. The pump was 
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working at flow rate of 0.1-1.0 ml/h. The distance between the end of the needle and the 
collector plate was fixed at 15-20 cm. A voltage was varied from 6 to 10 kV until a stable 
Taylor cone was achieved. All nanofibers were obtained at room temperature and relative 
humidity 30-50%. 
 
2.3. Crosslinking and stabilization of alginate-based electrospun fibers loaded with 
ciprofloxacin hydrochloride 
After electrospinning fibers were mechanically removed from the collector plate and 
ionically crosslinked. Fibers were soaked in ethanol (1 min), followed by calcium chloride 
solution (2 wt.%) in 1:5 ethanol:water (10 min). Subsequently, fibers were removed from 
calcium chloride solution and lyophilized. 
 
2.4. Characterization of the electrospun fibers 
Fiber mats were characterized by IR spectroscopy (Vertex 70, Bruker) using an ATR 
Golden Gate accessory. Furthermore, a scanning electron microscopy (SEM, FEI XL30) was 
applied for fibers characterization. Fiber diameters and standard deviations on 200 fibers per 
sample were measured using ImageJ program. 
 
2.5. Ciprofloxacin hydrochloride encapsulation efficiency 
The ciprofloxacin concentration was determined by UV-VIS spectrophotometry at 
277 nm (Lambda 35, Perkin Elmer). A standard calibration curve for ciprofloxacin were 
prepared. Encapsulation efficiency was calculated by the following equation (1): 
%100% 
T
LLE          (1) 
where T and L are respectively total and loaded amount of ciprofloxacin. Total amount of 
drug was recognized as an initial concentration of CpHCl in the synthesis solution. The 
loaded CpHCl concentration was calculated according to the calibration curve equation after 
dissolving the as-spun fiber in water. 
5 
 
The drug lost during the crosslinking was measured in ethanol and CaCl2 solution used 
in the process and the final ciprofloxacin load was obtain by difference between the amount 
remaining in the as-spun fibers according to the calculated LE% and the loss in the 
crosslinking solutions. 
 
2.6. Release of ciprofloxacin hydrochloride 
The release process was carried out in a continuous mode using a Shimadzu LC-10AT 
VP syringe pump. Crosslinked fibers were put into the syringe and rinsed with phosphate-
buffered saline (PBS) at 37ºC. Rinsed solution was collected in 1.5 ml eppendorf vials in 
different time intervals (1-10min; 20-60min; 1h-6h). The flow rate was 1ml/h, time of the 
whole ciprofloxacin hydrochloride release was 6 h. Collected samples were analyzed by UV-
VIS spectrophotometry at 277 nm (Lambda 35, Perkin Elmer). Amount of the released CpHCl 
was determined from ciprofloxacin calibration curve. 
 
2.7. Drug release mechanism 
In order to study the drug release mechanism from the fibers, various models were 
considered to fit the experimental data using Microsoft Excel software to execute and evaluate 
data modelling. The in vitro release data were evaluated to check the goodness of fit to 
Higuchi, Korsmeyer-Peppas, Linder-Lippold, Ritger-Peppas and Peppas-Sahlin models. All 
fitting models were performed by non-linear direct fitting and analyzed by the examination of 
the goodness of fit statistics such as the sum of squares due to error (SSE) and the adjusted R-
square (R2) by using a graph fitting software as an analysis tool. 
 
3. Results and discussion 
The main aim of this study was firstly to optimize procedure for electrospinning of bead-
free alginate fibers loaded with ciprofloxacin hydrochloride and foremost formed with high 
content of sodium alginate. Secondly, to characterize them taking into account a drug release 
kinetics. To help readers follow the performed protocols we summarize all studied 
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compositions of alginate fibers in Table 1, indicating figures in which the obtained fibers are 
presented. The bold letters indicates the images that present bead-free fibers. 
Table 1 
Summary of the composition of studied fibers (all set of experiments). 
AL 
wt% 
PEO Surfactant CpHCl 
wt% 
Figure 
MW wt% 
2.0 100 2.0 - - 1A 
600 2.0 - - 1B 
1000 2.0 - - 1C 
1.0 wt% Pluronic - 4A 
2000 2.0 - - 1D, 2D 
0.1 wt% Triton - 2E 
0.1 wt% Pluronic - 2F 
3.0 1000 1.5 1.0 wt% Pluronic - 3A 
2 - - 2A 
0.5 wt% Triton - 2B 
0.5 wt% Pluronic - 2C, 3B 
1.0 wt% Pluronic - 3C, 4B 
0.02 8A 
0.08 8B 
0.10 6A, 8C 
4.0 1000 1.5 1.0 wt% Pluronic - 3D 
2 0.5 wt% Pluronic - 3E 
1.0 wt% Pluronic - 3F, 4C 
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1.0 wt% Pluronic 0.10 6B, 7A, 7B 
5.0 1000 2 1.0 wt% Pluronic - 4D 
 
 The presence of beads in the fibers is indicative of an unstable process [Siavash S. et al. 
Polymer Eng. Sci. 55 (2015) 2576-2582], as consequence the reproducibility of the obtained 
material is very low. Besides, only well-defined bead-free fibers can assure slow and 
sustained kinetics of a drug release, so important parameter in case of treatment of the 
infected wounds. It is well-documented that a drug release kinetics for polymeric capsules and 
fibers is totally altered. First of all, morphology of these formulations offers different surface 
area to volume ratios – the higher value yielding the higher rate of drug release in the case of 
fibers (for fixed drug loading). However, both theoretical predictions and the experimental 
data are in excellent agreement that polymeric fibers (PLGA) exhibit slower and less efficient 
releasing of a drug in comparison with capsules [2]. Thus, one would expect that in the case 
of beaded fibers the profiles of drug release could be complicated and unpredictable.  
3.1. Effect of additional polymer on formation of electrospun alginate fibers 
Due to the high viscosity and high electrical conductivity of alginate solutions, 
formation of fibrous structures by electrospinning of pure alginate is really difficult and leads 
to generation of sprayed droplets or short fibers embedded with beads. Another cause that 
limited the electrospinnability of aqueous sodium alginate solutions is the high surface 
tension. To solve these problems different approaches were used (i) incorporation of an 
additional well-electrospinable polymer, (ii) application of surfactants or/and (iii) addition of 
co-solvent to alginate solution [23]. The first solution implies the use of flexible and 
uncharged synthetic polymers (e.g. PEO and PVA) that via the hydrogen bonds formed 
between alginate and these polymers, decrease the repulsive force among polyanionic 
molecules and facilitate the chain entanglement [12]. Beside, Saquing et al. found that PEO 
favorably reduces surface tension, which facilitates electrospinning [20]. PEO is a unique 
class of non-ionic water-soluble biodegradable biopolymer, that due to its excellent 
biocompatibility, biodegradability and very low toxicity is proposed for the use in many 
biomedical applications [7, 22]. What is also noteworthy, PEO is approved by Food and Drug 
Administration. 
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 Since it is known that the polymer molecular weight modify the solutions rheological 
properties and as consequence has influence in the fiber size and morphology [24] PEO with 
four different average molecular weights as a carrier polymer was tested. The initial attempt at 
electrospinning of alginate-PEO fibers resulted in droplets or beaded fibers but no uniform 
nanofibers (Fig. 1). 
 
Fig. 1. SEM images of electrospun alginate fibers: a) 2.0 wt.% AL, 2.0 wt.% PEO 100 kDa, 
b) 2.0 wt.% AL, 2.0 wt.% PEO 600 kDa, c) 2.0 wt.% AL, 2.0 wt.% PEO 1000 kDa and d) 
2.0 wt.% AL, 2.0 wt.% PEO 2000 kDa. 
 
It was concluded that the higher molecular weight of the PEO better fibers with fewer beads 
are obtained. This is in agreement with work on the role of PEO as the “carrier polymer” in 
alginate-based nanofibers extensively studied by Saquing et al.. It was demonstrated that 
electrospining of alginate is only possible by blending with an appropriate polymer with a 
high molecular weight. It was speculated that PEO-PEO interactions of the high molecular 
weight producing sufficient chain entanglements in the resulting polymer blend solution play 
a key role in “carrying” the alginate from solution during electrospining [20].  
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3.2. Effect of surfactant on formation of electrospun alginate fibers 
 The second proposed solution of improvement of electrospinning from alginate 
solutions concerns addition of surfactant. Besides, the amount of alginate in the blend can be 
increased with the addition of small amounts of surfactant. A nonionic surfactant plays a 
important role to the mat formation during electrospinning process, especially influences on 
morphology of fibers. Reducing the surface tension and the suppression of bead’s defects are 
two of the most important tasks that surfactants meet [22]. Triton X-100 and Pluronic F-127 
are the most commonly used surfactants in electrospinning of alginate-based nanofibers. Both 
have hydrophilic PEO blocks, however the hydrophobic polypropylene oxide (PPO) block 
from Pluronic F-127 is less toxic than the alkyl benzene block in Triton X-100. For this 
reason Pluronic F-127 is a more viable material for biomedical applications and it is a FDA-
approved surfactant [21, 22]. 
 The addition of small amounts of Triton X-100 or Pluronic F-127 to the sample 
generates bead-free fibers when using PEO 1000 kDa, as shown in Fig. 2 (A-C). In cases of 
PEO with MW 2000 kDa the addition of Triton X-100 produce fibers without beads but with 
very heterogeneous diameter. With the addition of Pluronic F-127 even more heterogeneous 
fibers were produced (Fig. 2 F). This could be related to the PEO surfactant interaction that 
modifies the surface tension of solutions leading to unfavorable electrospinning conditions. 
The surface tension was one of the most important parameters during the electrospinning 
process and it was previously reported that the polymer-surfactant interaction decrease the 
surface tension of solution [25]. Thus, in further study we decided to use PEO 1000 kDa. 
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Fig. 2. SEM images of electrospun a) alginate fibers without surfactant (3.0 wt.% AL, 
2.0 wt.% PEO 1000 kDa) and with addition of surfactant b) 0.5 wt.% Triton X-100, c) 
0.5 wt.% Pluronic F-127 as well as d) alginate fibers without surfactant (2.0 wt.% AL, 
2.0 wt.% PEO 2000 kDa) and with addition of surfactant e) 0.1 wt.% Triton X-100, f) 
0.1 wt.% Pluronic F-127. 
 
 Since the potential use of alginate-based nanofibers is biomedical applications, there is 
a strong need to use only non-toxic reagents. Therefore in further study, we focused on 
application of Pluronic F-127 as a main surfactant that effectively suppresses formation of 
bead defects in the investigated systems (Fig. 3). 
11 
 
 
Fig. 3. SEM images of electrospun alginate fibers: a) 3.0 wt.% AL, 1.5 wt.% PEO 1000 kDa, 
1.0 wt.% Pluronic F-127, b) 3.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 0.5 wt.% Pluronic F-127, 
c) 3.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127, d) 4.0 wt.% AL, 1.5 wt.% 
PEO 1000 kDa, 1.0 wt.% Pluronic F-127, e) 4.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 0.5 wt.% 
Pluronic F-127, f) 4.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127. 
 
Free from beads and defects nanofibers with higher content of sodium alginate than 
additional polymer and surfactant have been successfully obtained only in case of 3.0 wt.% 
AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127 (Fig. 3C) and 4.0 wt.% AL, 2.0 wt.% 
PEO 1000 kDa, 1.0 wt.% Pluronic F-127 (Fig. 3F). They exhibited cylindrical shape and 
regular morphology with average diameter of 136±33 nm and 148±30 nm in case of lower 
and higher content of AL, respectively. Only simultaneous incorporation of the additional 
polymer and the surfactant resulted in nanofibers with perfect uniformity and structural 
integrity. Increase of only one of these components in blend alginate solution did not assure 
formation of bead-free fibers (Fig. 3). Thus, both well-electrospinable polymer (PEO) and a 
surfactant (in general, Triton X-100 or Pluronic F-127) have a substantial effect on 
electrospinning processability of alginate nanofibers. 
 Our findings concerning the important role of surfactant in formation of uniform 
nanofibers with high content of alginate are in agreement with other authors [20-22]. For 
instance, Bonino et al. as well concluded that the addition of small amount of a surfactant 
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(1.0 wt.%) effectively lowers the surface tension of polymer solution, supports formation of 
uniform nanofibers and enhances concentration of alginate and morphology of electrospun 
fibers from alginate-PEO blend solutions [21]. 
 
3.3. Influence of alginate concentration on alginate electrospun fibers formation 
 Furthermore, influence of increasing alginate concentration and constant concentration 
of Pluronic F-127 (1.0 wt.%) on formation of nanofibers with respectable uniformity and 
structural integrity has been investigated. SEM images of the electrospun fibers with 
increasing content of alginate are shown in Fig. 4. 
 
Fig. 4. SEM images of different electrospun alginate fibers: a) 2.0 wt.% AL, 2.0 wt.% PEO 
1000 kDa, 1.0 wt.% Pluronic F-127, b) 3.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% 
Pluronic F-127, c) 4.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127, d) 
5.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127. 
 
 Smooth and uniform nanofibers were obtained in range of 2-4 wt.% of sodium alginate 
with constant concentration of PEO 1000 kDa (2.0 wt.%) and Pluronic F-127 (1.0 wt.%) 
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(Fig. 4A-C). Increased alginate concentration resulted in no significant trend in nanofiber 
sizes changes (taking into account the determined standard deviation error). Average size 
calculated for approximately 200 fibers was estimated to be 125±29 nm, 109±24 and 177±50 
nm for 2.0, 3.0 and 4.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127, 
respectively. Increase of alginate concentration to 5.0 wt.% without changing of PEO 
1000 kDa and surfactant content resulted in droplets formation (Fig. 4D). It can be supposed 
that electrospinning was impossible because of high conductivity of alginate. This also 
confirms that addition of both PEO and surfactant is necessary to generate bead-free fibers. 
 
3.4. Crosslinking and stabilization process of unloaded fibers 
PEO, necessary to improve the electrospinnability of the alginate, is a non-toxic, 
biologically inert and water soluble polymer. However, according to the literature [26] it can 
be remove from the fiber during the crosslinking process. In order to confirm the removal of 
the PEO, ATR-FTIR was used to examine the ciprofloxacin unloaded fibers before and after 
the treatment. Pure PEO, Pluronic F-127 and alginate spectra were included as references 
(Fig. 5). 
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Fig. 5. FTIR spectra of a) AL, b) PEO 1000 kDa, c) Pluronic P-127, d) untreated and e) 
treated 4.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127 fibers. 
 
AL spectrum shows a characteristic peaks at 1595 and 1407 cm-1 related to the 
asymmetric and symmetric stretching of –COO groups, respectively, and the asymmetrical 
C−O−C stretching modes at 1029 cm−1 [4, 27]. While, PEO spectrum presents characteristic 
peaks at 2886, 1100 and 962 cm-1 related to the stretching, rocking and twisting of the 
methylene group. The band at 842 cm-1 can be assigned to the stretching vibration of COC 
and CC molecular bonds [28]. Similar spectrum was obtained for Pluronic F-127 since it is a 
triblock copolymer of PEO and polyproylene oxide [29]. As expected the spectrum of 
electrospun fibers before treatment exhibited all these peaks confirming the presence of PEO 
in the fibers. However, after treatment these peaks were no longer present in the fiber 
spectrum, in agreement with the complete removal of PEO and Pluronic F-127 from the 
fibers. Besides, there is a shift of the peak related to symmetric stretching of –COO groups to 
higher frequency 1604 cm-1 that could be attributed to an increase of the interaction between 
these groups of alginate and Ca2+ ions [11]. 
 
3.5. Formation of alginate electrospun fibers loaded with ciprofloxacin hydrochloride 
 Mixing antibiotics in the polymer solution prior to electrospinning is an easy method 
to load large quantities of a drug into practically any polymeric nanofibers. However, there 
are disadvantages of the resulting systems, mainly the loaded drug tends to leach out rapidly 
from the fibrous mats in an aqueous solution. This effect is termed “burst release” and is 
widely described in scientific literature [2, 30-32]. 
 Using the same procedure as described in the previous sections, alginate-PEO blended 
solutions with the addition of ciprofloxacin hydrochloride were electrospun (Fig. 6). 
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Fig. 6. SEM images of different electrospun alginate fibers loaded with ciprofloxacin: a) 
3.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127, 0.1 wt.% CpHCl 
(1.0 mg/ml) and b) 4.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127, 
0.1 wt.% CpHCl (1.0 mg/ml). 
 
The resulting nanofibers after addition of CpHCl were smooth and without any beads. 
It was concluded that the addition of another component i.e. antibiotic to the electrospinning 
mixture did not changed significantly electrospinability of sodium alginate. Desirable smooth 
and flexible alginate fibers with addition of PEO 1000 kDa (2.0 wt.% PEO) and Pluronic F-
127 (1.0 wt.%) were obtained with the average size of 119±36 nm and 161±32 nm for 3.0 and 
4.0 wt.% AL, respectively. 
In general, the morphology of electrospun nanofibers depends on solution parameters 
such as conductivity, viscosity, and surface tension [6, 12, 22, 33]. When an aqueous drug 
solution is added into a polymer solution, the viscosity and surface tension of the mixed 
solution alter slightly, usually overall effect is negligible. Meanwhile, the conductivity of the 
solution can be increased by the presence of ionized drug molecules (although the exact value 
of increase in conductivity is not known), which increases the charge density of the jet 
resulting in the fibrous morphology [2, 34-36]. In our case the electrospinning process was 
possible and resulted in formation of regular fibers 
 
3.6. Post-treatment – stabilization and cross-linking of loaded fibers 
As expected, the as-prepared nanofibers were highly water-soluble and dissolved in 
water-based media. Therefore, to improve the stability of the electrospun mats they were 
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immersed in ethanol for 1 min and then in ethanol solution of CaCl2 for 10 min. 
Consequently, stabilization and cross-linking processes occurred in these conditions. The 
electrospun alginate fibers before and after post-treatment are presented in Fig. 7. 
 
Fig. 7. SEM images of electrospun alginate fibers loaded with ciprofloxacin 4.0 wt.% AL, 
2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-127, 0.1 wt.% CpHCl (1mg/ml) a) before and 
b) after stabilization and cross-linking processes. 
 
The morphology of the stabilized and cross-linked alginate nanofibers changed 
slightly after applied post-treatment. They puffed up and interfused inconsiderably, however, 
what is noteworthy, the nanofibrous structure was maintained. The increase in the fibers’ 
diameter from 161±32 nm to 181±45 nm was the only noticeable effect that was observed 
after treatment procedure. The increase in diameter has been also observed by other authors 
and was attributed to the swelling during PEO dissolution [37]. It was concluded that the 
alginate-based nanofibers were successfully ionically cross-linked in a calcium solution 
without the need of the cytotoxic chemical cross-linkers application (e.g., glutaraldehyde). 
Determined diameter of obtained alginate fibers is in agreement with that published by other 
authors. For example, Bonino et al. obtained uniform nanofibers containing alginate, PEO 
(600 kDa) and Pluronic F-127 with the average fiber diameters ~150 nm, independently on 
the molecular weight of used alginate (37 and 196 kDa). Moreover, the authors speculate that 
the final fiber diameter is not dependent on solution composition but rather on the similarities 
in the solution storage and processing conditions such as viscosity, temperature, and humidity 
[21]. The above-mentioned speculations were confirmed by these authors, who showed the 
influence of relative humidity on diameter of electrospun fibers (blends of alginate (37 kDa), 
PEO (600 kDa), Pluronic F-127 as surfactant). It was concluded that the increased relative 
humidity results in decrease of fiber size [22]. 
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3.7. Loading efficiency 
 For nanofibers with 3.0 wt.% of alginate mixed with 2.0 wt.% of PEO 1000 kDa and 
1 wt.% of surfactant (Pluronic F-127) it was possible to load even 1.0 mg/ml of CpHCl in the 
precursor solution without any adverse effect on the structure, morphology and size of the 
resulting nanofibers (Fig. 8). According with these results and in order to have the maximum 
ciprofloxacin load in the fibers, the materials hereafter were prepared using 1.0 mg/ml of 
CpHCl. 
 
Fig. 8. SEM images of as-electrospun alginate fibers loaded with different concentration of 
ciprofloxacin hydrochloride: a) 3.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% Pluronic F-
127, 0.02 wt.% CpHCl (0.2 mg/ml), b) 3.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 1.0 wt.% 
Pluronic F-127, 0.08 wt.% CpHCl (0.8 mg/ml) and c) 3.0 wt.% AL, 2.0 wt.% PEO 1000 kDa, 
1.0 wt.% Pluronic F-127, 0.1 wt.% CpHCl (1.0 mg/ml). 
 
The amount of ciprofloxacin measured in the as-spun fibers (3.0 wt.% AL, 2.0 wt.% 
PEO 1000 kDa, 1.0 wt.% Pluronic F-127, 0.1 wt.% CpHCl (1.0 mg/ml)) was 
1.13 ± 0.02 wt.% implying a LE value of 82.7 ± 1.5%. In order to known the drug loading 
after stabilization and crosslinking processes, the amount of CpHCl in crosslinking and 
stabilization solutions was quantify. It was calculated that 61.6 ± 6.9% of the drug present in 
the as-spun fibers was lost during the post-treatment. As consequence the final fibers contain 
1.21 ± 0.16 wt.% ciprofloxacin (assuming that all PEO and Pluronic F-127 were eliminated 
during the crosslinking process), what gives a LE for the complete process of 51.0 ± 6.7 %. 
 
3.8. Release of ciprofloxacin hydrochloride 
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In general, in case of nanofibers electrospun in such a way that the drug is mixed with 
polymer prior to manufacturing, the release profile in an aqueous environment is found to 
have a biphasic kinetics. An initial burst release is usually followed by a much slower second 
process. The high burst release can be ascribed mainly to the fact that the small diameter and 
the high surface area in the nanofibers guarantee short diffusion pathway and are favorable to 
mass transfer of the drug [2, 35, 36]. 
Fig. 9 shows the profile of CpHCl release from fibers, expressed as cumulative 
percentage of drug release versus time. 
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Fig. 9. Ciprofloxacin hydrochloride cumulative percent release profile and Peppas-Sahlin 
model fitting and R/F ratio profile. In the case of drug release profile a standard deviation for 
each time point is given. 
 
After 20 h only around 24% of the total loaded drug was released suggesting that the rest of 
CpHCl is still inside the fibers. The slightly increasing slope of the curve suggests that the 
releasing would continue after that time, but the amount of drug in the media was 
undetectable by our UV-Vis equipment. This behavior is different from the reported by Sibaja 
et al. [38] for alginate-chitosan fibers that release about 40-50 % of the drug in the first hour. 
It would indicate that the crosslinking and stabilization processes avoid the fast drug release 
in the prepared AL fibers. As well, Hajiali et al. [4] demonstrated that with increasing the 
duration time of the post-treatment with trifluoroacetic acid, degradation rate of alginate 
nanofibers is prolonged. Thus, any strategy to enhance the stability and to control 
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degradability of the broad utilized electrospun sodium alginate fibers is highly required, since 
application of these polymeric scaffolds, in for instance tissue engineering, is now strongly 
limited by their high solubility and the difficulty in adjustment of degradation dynamic and a 
drug release kinetics. What is noteworthy, the obtained by us release profile is similar to the 
one obtained for crosslinked sodium alginate/PEO hydrogel membranes by Mallikarjuna et al. 
[27]. However, in the case of our fibers after 20 hours only about 24 % was released, while 
for hydrogels less than 14 hours were necessary to achieve 60 % drug release in the best case. 
Several models were used to evaluate the release kinetics (results not shown) but 
Peppas-Sahlin model was the only one that fits for the CpHCl release data giving good R2 
values: 
nnt tktk
M
M 2
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
                    (2) 
where k1, k2, and n are constants, Mt/M∞ is the drug release fraction at time t. The first term on 
the right-hand side represents the Fickian diffusional contribution (F) and the second one is 
the case-II relaxational contribution (R) [39]. The obtained parameters are shown in Table 2; 
the R2 values for the rest of models were lower than 0.985. 
Table 2 
Peppas-Sahlin parameters. 
Peppas-Sahlin parameters
k1 5.82 ± 0.25 
k2 -0.36 ± 0.03 
n 0.67 ± 0.02 
R2 0.995 
 
The obtained n value is in the range reported for cylinders (0.45 < n < 0.89) with combined 
transport mechanism [40]. The fact that k1 is higher than k2 indicates that Fickian diffusion 
makes the predominant contribution to ciprofloxacin hydrochloride from alginate fibers 
release [41, 42]. The negative value obtained for k2 should be interpreted in terms of a 
relaxation/dissolution mechanism insignificant compared to the diffusion process. Alginate is 
a highly soluble compound, but after the cross-linking process the dissolution would be 
avoided and the fibers entanglement would hinder the relaxation. The R/F profile provides 
information about the ratio of magnitude of diffusion due to polymer relaxation and Fickian 
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diffusion. In other words, R/F profiles having values >1 suggest polymer relaxation-mediated 
diffusion is predominant as compared to the Fickian diffusion. In our case the R/F ratio 
profile (Fig. 9), calculated using the equation R/F=(k2/k1)tn, is lower than 1 in all the studied 
range [42, 43] indicating also the predominance of the Fickian diffusion. It is interesting to 
see that with the increase in the experimental time there was an increase in the polymer 
relaxation/diffusion ratio. It was expected that after several minutes of immersion in PBS 
some relaxation processes start even in the crosslinked fibers. The obtained Peppas-Sahlin 
parameters confirm that the CpHCl release follows a diffusion-controlled mechanism. 
 
4. Conclusions 
The resulting nanofibers were formed with high content of sodium alginate, a natural 
highly biocompatible polysaccharide, as well as an addition of PEO and Pluronic F-127 (an 
ethylene oxide(EO)/propylene oxide (PO) block copolymer), both Food and Drug 
Administration approved polymers. What is noteworthy, a carrier polymer (PEO) was 
completely removed from alginate fibers during their crosslinking with calcium ions and 
stabilization process in ethanol. Stable alginate nanofibers loaded with ciprofloxacin 
hydrochloride revealed the average diameter of 109 nm and 161 nm for unloaded and loaded 
fibers, respectively. Loading efficiency was determined to be 51%. While, the study on the 
release kinetics proved the combined transport mechanism with the predominant contribution 
of Fickian diffusion. The use of biopolymers as well as non-toxic solvents and crosslinkers 
makes the resultant scaffolds promising for various biomedical applications such as wound 
healing, regenerative medicine and drug delivery systems. It can be also supposed that since 
the produced alginate scaffolds are free from cytotoxic chemicals and possess appropriate 
structural properties they can promote the attachment and proliferation of cells. 
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AL – sodium alginate 
CpHCl – ciprofloxacin hydrochloride 
FDA – Food and Drug Administration 
PCL – polycaprolactone, 
PLA – polylactic acid, 
PGLA – poly(lactic-co-glycolic acid), 
PEO – polyethylene glycol, poly(ethylene oxide), 
PVA – poly(vinyl alcohol), 
PVP – poli(vinylpyrrolidone), 
ECMs – extracellular matrix, 
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